Intervention/Treatment
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Thyroid Eye Disease
Conditions
Thyroid Eye Disease
Trial Timeline
Jan 31, 2024 → Jun 23, 2025
NCT ID
NCT06179875About Intervention/Treatment
Intervention/Treatment is a phase 3 stage product being developed by Viridian Therapeutics for Thyroid Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06179875. Target conditions include Thyroid Eye Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06179875 | Phase 3 | Completed |
Competing Products
20 competing products in Thyroid Eye Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib + Placebo + Lenvatinib | Eisai | Phase 3 | 77 |
| Irofulven + capecitabine | Eisai | Phase 2 | 52 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Approved | 85 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Bexarotene | Eisai | Phase 1 | 33 |
| Lenvatinib + Lenvatinib matching placebo | Eisai | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| E7080 capsule | Eisai | Phase 2 | 52 |
| Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort) | Eisai | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |